Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
The U.S. Food and Drug Administration (FDA) announced its plans to end the mandatory animal testing of new drugs, a move that sent AI-enabled biotech companies such as Recursion Pharmaceuticals Inc. RXRX and Ginkgo Bioworks Holdings Inc. DNA rallying last week. What Happened: On Thursday, the new FDA commissioner, Martin Makary, announced a major reform ...










